Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.
2026-10-12 08:26
•Keith Speights •The Motley Fool
•• • Axe Cap view
Eli Lilly’s 8% Pullback: Time to Watch, Not Rush
After a strong rally, Eli Lilly's recent dip looks more like profit-taking than trouble.
Eli Lilly’s recent 8% slide comes right after a remarkable 41% jump over the past year. The pullback feels like classic profit-taking rather than any shift in fundamentals. Their GLP-1 drugs like Mounjaro and Zepbound continue to dominate growth conversations. Wall Street remains confident, with 20 of 23 analysts on the buy side and a 16% upside target still intact. For South African investors, the direct stock play is limited, but the USD/ZAR offers a way to hedge or benefit. A stronger dollar generally pressures the rand, which can reshape returns from global stocks. Keep an eye on the dollar's strength because if a US recession or policy surprises hit, it could knock the currency — and rand gains — out of sync with expectations. This history of rebounds supports a patient approach rather than panic. Still, valuation multiples are high enough that a meaningful pullback can’t be ruled out. this is just our opinion and not financial advice
Watch Eli Lilly pullbacks but avoid chasing rallies. Hedge exposure through USD/ZAR if you hold US tech-heavy stocks locally. Be ready to trim if momentum fades.
- LLY
- USD/ZAR
- US interest rate shocks hitting dollar strength
- regulatory or pricing pressures on pharma stocks
6/10
Eli Lilly's stock has declined 8% recently after a 41% gain over 12 months. The pullback is attributed to profit-taking following a historic run. Despite concerns about product pricing and valuation multiples, the company's strong GLP-1 drug demand and growth prospects remain intact. Historical data shows Lilly has rebounded strongly from similar pullbacks, and Wall Street analysts remain overwhelmingly bullish with a consensus 16% upside target.
Our take is based on reporting first published by The Motley Fool.